Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ANPEP | P15144 | 2/20 | 0.34 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11765569 | 0.86 | PKM (0.50) | PKMKDM4EANPEPERAP2ALDH1A1 | |
| SCHEMBL27414997 | 0.86 | PKM (0.44) | PKMKDM4EANPEPERAP2ALDH1A1 | |
| SCHEMBL11765853 | 0.84 | PKM (0.48) | PKMKDM4EANPEPERAP2ALDH1A1 | |
| SCHEMBL2242929 | 0.82 | TSHR (0.46) | PKMKDM4EANPEPERAP2ALDH1A1 | |
| SCHEMBL27415012 | 0.81 | KDM4E (0.42) | PKMKDM4EANPEPALDH1A1KMT2A | |
| SCHEMBL4293846 | 0.80 | PKM (0.40) | PKMKDM4EANPEPERAP2ALDH1A1 | |
| SCHEMBL17351928 | 0.80 | TSHR (0.52) | PKMKDM4EANPEPERAP2ALDH1A1 | |
| SCHEMBL3424460 | 0.80 | PKM (0.40) | PKMALDH1A1 | |
| SCHEMBL24459668 | 0.78 | ANPEP (0.50) | PKMANPEPERAP2ALDH1A1 | |
| SCHEMBL6249621 | 0.78 | ANPEP (0.50) | PKMANPEPERAP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215770-A1 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | US | disclosed |
| US-7402585-B2 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070561-A1 | Substituted quinazoline derivatives as inhibitors of aurora kinases | AURKC, AURKA, AURKB | PKM 417/4885KDM4E 1346/4885ANPEP 1963/4885 |
| US-20090215770-A1 | Substituted Quinazoline Derivatives as Inhibitors of Aurora Kinases | AURKC, AURKA, AURKB | PKM 670/4885KDM4E 1249/4885ANPEP 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.